Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • Remdesivir CAS 1809249-37-3 Supplier and Production Information for Pharmaceutical Use

Aug . 18, 2024 12:42 Back to list

Remdesivir CAS 1809249-37-3 Supplier and Production Information for Pharmaceutical Use



Remdesivir A Comprehensive Overview of its Manufacturer


Remdesivir, a novel antiviral medication, has gained significant attention as a potential treatment for viral infections, particularly COVID-19. It is a nucleoside analog that inhibits viral RNA synthesis, making it effective against RNA viruses such as SARS-CoV-2. The CAS number for Remdesivir is 1809249-37-3, and its development has involved various manufacturers and pharmaceutical companies throughout its history.


Remdesivir A Comprehensive Overview of its Manufacturer

The development of Remdesivir was expedited in response to the global health crisis caused by the SARS-CoV-2 virus. In January 2020, researchers began to investigate the drug’s efficacy against this novel coronavirus, leading to clinical trials that evaluated its safety and effectiveness. Gilead Sciences quickly collaborated with various health organizations and governments to facilitate widespread testing and ultimately secure emergency use authorization for Remdesivir in May 2020. This collaboration underscored the critical importance of public-private partnerships in addressing urgent health challenges.


remdesivir cas1809249-37-3 manufacturer

remdesivir cas1809249-37-3 manufacturer

As an intravenous medication, Remdesivir is typically administered in a hospital setting, making it more challenging to deploy than oral antiviral medications. However, its ability to reduce the duration of COVID-19 symptoms and prevent severe complications has made it a valuable treatment option, particularly for patients requiring hospitalization. Clinical trials have demonstrated that when given early in the course of infection, Remdesivir can significantly improve recovery times, leading to its recommendation by healthcare authorities in many countries.


Although Gilead Sciences is the primary manufacturer of Remdesivir, the increased demand for the drug during the pandemic led to collaborations with other pharmaceutical companies for production. To meet global needs, Gilead initiated compulsory licensing agreements with several manufacturers, especially in low- and middle-income countries. This strategy allowed generic versions of Remdesivir to be produced, enhancing accessibility to the drug for those in need. Companies in India, Bangladesh, and other countries have played a crucial role in this effort, producing affordable generic alternatives that have helped expand treatment access during the pandemic.


The pricing of Remdesivir has been a point of contention as well. Gilead Sciences has priced the drug at a level that reflects the extensive research and development efforts, but critics argue that high costs can hinder access for many patients. In response, Gilead has engaged in discussions to price the drug reasonably in different regions, particularly where healthcare systems are strained.


In conclusion, the journey of Remdesivir from a research project to a globally recognized antiviral treatment exemplifies the dynamic nature of pharmaceutical development. Amidst a pandemic, Gilead Sciences has not only worked tirelessly to manufacture and distribute Remdesivir but also to collaborate with other manufacturers to ensure that the drug is accessible worldwide. As researchers continue to study the long-term impacts and possible extended uses of Remdesivir, its role in antiviral therapy solidifies, demonstrating the power of science and innovation in the face of global health crises. The ongoing dialogue about pricing, accessibility, and production will be vital as the world navigates future health challenges.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
sdSindhi
en_USEnglish afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu sdSindhi